ArticleFrontiers in genetics2026
Multi-omics mendelian randomization integrating GWAS and eQTL data revealed potential drug target for irritable bowel syndrome.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Irritable bowel syndrome (IBS) is a common gastrointestinal disorder mainly affecting the young and female with limited therapeutic options, necessitating the identification of novel drug targets. This study aimed to identify and prioritize new, genetically validated drug targets for IBS by leveraging large-scale human genetic data. Methods: We conducted a systematic, druggable genome-wide Mendelian randomization (MR) analysis to evaluate the causal effects of 5,642 potential druggable protein-coding genes on IBS risk. The analysis integrated summary statistics from the largest available IBS genome-wide association study (GWAS), including 53,400 cases and 433,201 controls, with comprehensive blood expression quantitative trait loci (eQTL) data. Significant findings were further validated using colocalization analysis. A phenome-wide association study (PheWAS) was performed to assess the potential for on-target adverse effects. Finally, potential therapeutic compounds were predicted using the Drug Signatures Database (DSigDB) and molecular docking. Results: The MR analysis identified eight genes with potential causal associations with IBS. Following rigorous validation with colocalization analysis, EP300 and P2RY14 emerged as the most promising candidate targets. Genetically predicted higher expression of both EP300 (OR: 1.128, 95% CI: 1.079-1.180) and P2RY14 (OR: 1.118, 95% CI: 1.067-1.172) was suggestively causally associated with an increased risk of IBS. The PheWAS analysis indicated that EP300 and P2RY14 did not show genome-wide significant associations with any other phenotypes. Additionally, molecular docking predicted that existing compounds, such as captopril and menadione, could effectively bind to the EP300 protein. Conclusion: Our study provides genetic evidence establishing EP300 and P2RY14 as promising drug targets for the treatment of IBS, laying a foundation for future drug development and repurposing efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.